Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash turns negative

Q2 FY2026 net change in cash was -$108.36M, compared with $24.69M a year earlier. Trailing-twelve-month net change in cash was $22.98M. Over 3 fiscal years it compounded at -17.0% a year.

Context

  • Net change in cash amounted to 202.1% of revenue in FY2025, down 140.6 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly net change in cash holds near -$108.36M or moves back toward the trailing-twelve-month quarterly average of $5.74M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$108.36M+22.1% QoQ
Last fiscal yearDec 2025
$150.9M-25.1% YoY
LTMJun 2026
$22.98M-55.0% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-538.9%——
1 year-25.1%——
3-year CAGR-17.0%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
150.9M USD
Year-over-year change
-25.1%
4-year CAGR
+52.1%

Net Change in Cash vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's LTM Jun 2026 net change in cash of $22.98M is the 3rd largest of the 4 companies compared; the peer median is $6.33M.
  • Its year-over-year change of -55.0% is the 3rd highest of 4, against a peer median of -11.4%.
  • Net change in cash amounts to 41.9% of revenue for RXRX, versus a peer median of 478.0%.
RXRX Competitors Peer median
Net Change in Cash for RXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MAZEMaze Therapeutics, Inc.LTM Mar 2026$95.61M -136.2%-57.8%478.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$60.32M -11.4%—1673.8%
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$22.98M -55.0%-17.0%41.9%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$6.33M +130.7%-31.6%61.1%
Peer median (excluding RXRX) $6.33M-11.4%-44.7%478.0%

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(186.48M)(239.48M)(328.07M)(463.66M)(644.76M)
Depreciation & Amortization8.41M11.76M24.4M36.49M83.7M
Deferred Income Tax827K0000
Stock-Based Compensation14.84M27.91M53.5M81.69M111.22M
Change in Working Capital(306K)104.92M(44.26M)(38M)13.69M
Accounts Receivables114K(2K)(7.76M)(6.07M)32.94M
Inventory7.84M0000
Accounts Payables1.75M1.77M(987K)6.44M(2.62M)
Other Working Capital(10M)103.16M(35.51M)(38.37M)(16.64M)
Other Non-Cash Items4.1M11.37M6.64M24.31M64.34M
Operating Cash Flow(158.61M)(83.52M)(287.78M)(359.17M)(371.81M)
Capital Expenditures(39.8M)(37.36M)(11.96M)(13.7M)(6.47M)
Acquisitions (Net)231.95M01.84M277.1M0
Purchases of Investments(301.14M)000(3.81M)
Sales of Investments69.19M230.61M480K00
Other Investing Activities(231.95M)(300K)(597K)(3.35M)(6.6M)
Investing Cash Flow(271.74M)193.25M(10.23M)260.06M(16.87M)
Debt Repayment(12.8M)(90K)(766K)(4.44M)(8.43M)
Common Stock Issued462.9M143.71M128.09M300.42M532.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.44M10.72M12.81M8.14M(3M)
Financing Cash Flow458.54M154.35M140.13M304.12M521.53M
Effect of Forex Changes0(307K)188K(3.41M)18.04M
Net Change in Cash28.18M263.76M(157.69M)201.6M150.9M
Free Cash Flow(198.41M)(120.88M)(300.33M)(372.87M)(378.28M)

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.